At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 651 enrolled
Drug / intervention
LF formulation of IMVAMUNE® +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Multicenter Phase II Trial to Compare the Immunogenicity and Safety of a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects
In Brief
A Phase 2 clinical trial evaluating LF formulation of IMVAMUNE® and FD formulation of IMVAMUNE® for Smallpox. Completed, enrolled 651 participants across 3 sites.
Detailed Summary
A randomized, double-blind, multicenter Phase II trial to compare the immunogenicity and safety of a liquid-frozen and a freeze-dried formulation of IMVAMUNE (MVA-BN®) smallpox vaccine in vaccinia-naïve healthy subjects
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmallpox
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 2012
Enrollment StartMar 2013
Primary CompletionJan 2014
Study CompletionJun 2014
TodayJul 2026
First PostedAug 20, 2012
Enrollment StartMar 1, 2013
Primary CompletionJan 1, 2014
Study CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 13.9 years ago
Interventions
LF formulation of IMVAMUNE®biological
FD formulation of IMVAMUNE®biological